Dexcom Inc (DXCM) concluded trading on Wednesday at a closing price of $83.87, with 4.11 million shares of worth about $344.76 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 17.68% during that period and on February 12, 2025 the price saw a loss of about -2.91%. Currently the company’s common shares owned by public are about 390.60M shares, out of which, 385.55M shares are available for trading.
Stock saw a price change of -5.53% in past 5 days and over the past one month there was a price change of 5.05%. Year-to-date (YTD), DXCM shares are showing a performance of 7.84% which decreased to -30.38% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $62.34 but also hit the highest price of $142.00 during that period. The average intraday trading volume for Dexcom Inc shares is 3.44 million. The stock is currently trading -3.29% below its 20-day simple moving average (SMA20), while that difference is up 2.23% for SMA50 and it goes to -5.42% lower than SMA200.
Dexcom Inc (NASDAQ: DXCM) currently have 390.60M outstanding shares and institutions hold larger chunk of about 94.58% of that.
The stock has a current market capitalization of $32.76B and its 3Y-monthly beta is at 1.30. PE ratio of stock for trailing 12 months is 50.28, while it has posted earnings per share of $1.67 in the same period. Its PEG reads 2.88 and has Quick Ratio of 2.12 while making debt-to-equity ratio of 1.31. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for DXCM, volatility over the week remained 2.12% while standing at 2.53% over the month.
Stock’s fiscal year EPS is expected to rise by 10.95% while it is estimated to increase by 19.63% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Redburn Atlantic on February 03, 2025 offering a Buy rating for the stock and assigned a target price range of between $85 and $115 to it. Coverage by Robert W. Baird stated Dexcom Inc (DXCM) stock as an Outperform in their note to investors on January 16, 2025, suggesting a price target of $104 for the stock. On July 26, 2024, Robert W. Baird Downgrade their recommendations, while on July 26, 2024, JP Morgan Downgrade their ratings for the stock with a price target of $75. Stock get a Neutral rating from Redburn Atlantic on May 30, 2024.
